![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Proteo Inc (GM) | USOTC:PTEO | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 179.80 | 0.00 | 01:00:00 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A
AMENDMENT NO. 2
|X| ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended DECEMBER 31, 2007
OR
|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to ____________
Commission file number: 000-30728
PROTEO, INC. (Name of Small Business Issuer in Its Charter) NEVADA 88-0292249 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2102 BUSINESS CENTER DRIVE, IRVINE, CA 92612 (Address of principal executive offices) (Zip Code) (949) 253-4616 (Issuer's telephone number, including area code) |
NONE
(Former name, former address and former fiscal year, if changed since last
report)
Securities registered under Section 12(b) of the Act:
Title of each class Name of each exchange on which registered ------------------- ----------------------------------------- None None |
Securities registered under Section 12(g) of the Act: Common Stock, par value
$0.001
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes |_| No |X|
Indicate by checkmark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. |_|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes |X| No |_|
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. |X|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (check one):
Large accelerated filer |_| Accelerated filer |_| Non-accelerated filer |_| Smaller reporting company|X| |_|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes |_| No |X|
The approximate aggregate market value of voting stock held by non-affiliates of the registrant was $17,518,960 as of September 30, 2008.
23,879,350
(NUMBER OF SHARES OF COMMON STOCK OUTSTANDING AS OF AT SEPTEMBER 30, 2008)
DOCUMENTS INCORPORATED BY REFERENCE
None.
AMENDMENT NO. 2 TO THE ANNUAL REPORT ON FORM 10-KSB
FOR THE YEAR ENDED DECEMBER 31, 2007
EXPLANATORY NOTE
Proteo, Inc. (the "Company") is filing this Amendment No. 2 on Form 10-K/A (this "Amendment") to its Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007, which was filed on April 14, 2008 (the "Original Filing") and amended by Amendment No. 1 to Form 10-KSB, which was filed on July 31, 2008, to amend Part II Item 8A(T) of the Original Filing to include additional information required by such item.
Except as stated above or otherwise specifically described herein, no other changes have been made to the Original Filing, and this Amendment does not amend, update or change the financial statements or any other items or disclosures in the Original Filing. This Amendment does not reflect events occurring after the filing of the Original Filing or modify or update those disclosures, including any exhibits to the Original Filing affected by subsequent events. Information not affected by the changes described above is unchanged and reflects the disclosures made at the time of the Original Filing. Accordingly, this Amendment should be read in conjunction with our filings made with the Securities and Exchange Commission subsequent to the filing of the Original Filing, including any amendments to those filings.
Because of SEC Release No. 33-8876, the Company is filing this amendment using the applicable information requirements of Form 10-K. In a Form 10-K, "Controls and Procedures" are (temporarily) designated as Item 9A(T). As a result, Part II Item 8A(T) of the Original Filing is amended in its entirety to read as follows:
ITEM 9A(T) - CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are intended to ensure that information that would be required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time period specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including to Birge Bargmann our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
As required by Rule 13a-15 under the Exchange Act, our management, including Birge Bargmann our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2007. Based on that evaluation, Ms. Bargmann concluded that as of December 31, 2007, and as of the date that the evaluation of the effectiveness of our disclosure controls and procedures was completed, our disclosure controls and procedures were not effective to satisfy the objectives for which they are intended because of the material weakness described below.
INTERNAL CONTROLS OVER FINANCIAL REPORTING
MANAGEMENT'S ANNUAL REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING.
Section 404(a) of the Sarbanes-Oxley Act of 2002 requires that management document and test the Company's internal control over financial reporting and include in this Annual Report on Form 10-KSB a report on management's assessment of the effectiveness of our internal control over financial reporting.
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Exchange Act. Under the supervision and with the participation of our management, including Ms. Bargmann our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based upon the framework in Internal Control--Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). This evaluation and assessment led to the identification of a material weakness in our internal control over financial reporting as indicated below:
We lack the necessary depth of personnel with sufficient technical U.S. accounting expertise to ensure that our interim and annual financial statements (including the required footnote disclosures) can be prepared without material misstatements.
Based on this evaluation, we have concluded that as of December 31, 2007, and as of the date that the evaluation of the effectiveness of internal control over financial reporting was completed, our internal control over financial reporting was not effective to satisfy the objectives for which it is intended because of the material weakness described above.
Our plan to remediate the aforementioned material weakness is to utilize an outside consulting resource to prepare and review interim and annual financial statements.
Our December 31, 2007 annual report on Form 10-KSB does not include an audit report of our registered public accounting firm regarding internal control over financial reporting. In addition, management's report on internal control over financial reporting is not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management's report in the aforementioned annual report.
CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING.
During the fiscal year ended December 31, 2007, there were no changes in our internal control over financial reporting identified in connection with the evaluation performed during the fiscal year covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: October 21, 2008
PROTEO, INC.
(Registrant)
BY: /S/ BIRGE BARGMANN ------------------------------------ BIRGE BARGMANN CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER |
1 Year Proteo (GM) Chart |
1 Month Proteo (GM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions